https://ir.mustangbio.com/sec-filings/all-sec-filings/xbrl_doc_only/962
Mustang Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)
mustang bioquarterly reportpursuant toincsection
https://ir.mustangbio.com/sec-filings/all-sec-filings/xbrl_doc_only/99
Mustang Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)
mustang bioquarterly reportpursuant toincsection
https://ir.mustangbio.com/sec-filings/all-sec-filings/xbrl_doc_only/629
Mustang Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)
mustang bioquarterly reportpursuant toincsection
https://ir.mustangbio.com/sec-filings/all-sec-filings/xbrl_doc_only/915
Mustang Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)
mustang bioquarterly reportpursuant toincsection
https://ir.mustangbio.com/sec-filings/all-sec-filings/xbrl_doc_only/1823
Mustang Bio, Inc. Quarterly report [Sections 13 or 15(d)]
mustang bioquarterly reportincsections
https://ir.mustangbio.com/sec-filings/all-sec-filings/xbrl_doc_only/988
Mustang Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)
mustang bioquarterly reportpursuant toincsection
https://profiles.foxchase.org/en/clippings/mustang-bio-plummets-69-in-2024-underperforming-90-of-its-global-/
Mustang Bio plummets 69% in 2024, underperforming 90% of its global peers - Fox Chase Cancer Center
fox chase cancermustang bioplummetsunderperformingglobal
https://www.ig.com/jp/shares/markets-shares/mustang-bio-inc
Mustang Bio Inc
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs into potential cures for cancers and... [JP]
mustang bioinc
https://ir.mustangbio.com/sec-filings/all-sec-filings/xbrl_doc_only/1960
Mustang Bio, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]
mustang bioannual reportincsectionitem
https://www.ibtimes.co.uk/mustang-bio-stock-jumps-180-after-fda-grants-orphan-drug-status-brain-cancer-drug-1737772
Mustang Bio Stock Jumps 180% After FDA Grants Orphan Drug Status to Brain Cancer Drug | IBTimes UK
Jul 8, 2025 - Mustang Bio stock surged over 180% on Monday after the FDA granted its brain cancer drug candidate an orphan drug designation.
orphan drug statusmustang biobrain cancerstockjumps
https://ir.mustangbio.com/sec-filings/all-sec-filings/xbrl_doc_only/1301
Mustang Bio, Inc. Annual report pursuant to Section 13 and 15(d)
mustang bioannual reportpursuant toincsection
https://profiles.foxchase.org/en/clippings/monthly-mustang-bio-mbio-520-trails-88-of-stocks/
Monthly: Mustang Bio (MBIO: $5.20) trails 88% of stocks - Fox Chase Cancer Center
fox chase cancermustang biomonthlymbiotrails
https://ir.mustangbio.com/sec-filings/all-sec-filings/xbrl_doc_only/457
Mustang Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)
mustang bioquarterly reportpursuant toincsection
https://ir.mustangbio.com/sec-filings/all-sec-filings/xbrl_doc_only/1961
Mustang Bio, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]
mustang bioannual reportincsectionitem
https://ir.mustangbio.com/sec-filings/all-sec-filings?page=21
All SEC Filings :: Mustang Bio, Inc. (MBIO)
all sec filingsmustang bioincmbio
https://ir.mustangbio.com/sec-filings/quarterly-reports/xbrl_doc_only/8
Mustang Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)
mustang bioquarterly reportpursuant toincsection